Genomics Core

基因组学核心

• 批准号: 10490407
• 负责人: Nikhil Wagle
• 金额: $ 1.61万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-27 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10490407
• 关键词: Address; African American; African ancestry; Androgen Receptor; BRCA2 gene; Bioinformatics; Biomedical Research; Biostatistical Methods; Boston; CHD1 gene; Cancer Biology; Cancer Center; Code; DNA Sequence; Dana-Farber Cancer Institute; Data; Data Analyses; Education and Outreach; Educational workshop; Fees; Frequencies; Genomic approach; Genomics; Goals; Infrastructure; Institution; Instruction; Lead; Learning; Malignant neoplasm of prostate; Massachusetts; Minority-Serving Institution; Modeling; Outcome; Population; Prostatic Neoplasms; RNA; Receptor Signaling; Research; Research Design; Research Personnel; Research Training; Resources; Reverse Transcriptase Polymerase Chain Reaction; Risk; SNP genotyping; Structure; Students; Technology; Training; Underrepresented Populations; Underrepresented Students; Universities; Untranslated RNA; anticancer research; base; cancer health disparity; cancer initiation; cancer risk; cost; design; education research; experience; genomic data; health disparity populations; innovation; instrumentation; men; nano-string; next generation sequencing; novel; personalized cancer therapy; programs; single cell sequencing; therapy resistant; tool; tumor progression

SUMMARY A critical gap often exists at institutions serving underserved health disparity populations and underrepresented students (ISUPS) between access to Genomics technologies and the high costs associated with the required instrumentation, technical proficiency, and analytical expertise. The Genomics Core (GC) addresses this gap by providing expert and affordable access to high-throughput genomics technologies on a reduced fee basis for all Partnership investigators. The GC benefits the entire Partnership by providing innovative approaches to explore early project ideas, and by working with Partnership investigators and their trainees to facilitate the use of genomics technologies to build sustainable cancer biology and cancer disparities research. To accomplish these goals, the GC (through the auspices of the Center for Personalized Cancer Therapy, CPCT) provides front-line genomics-related technologies, as well as bioinformatics support for data analysis, to Partnership investigators through an affordable reimbursement model. The GC proposes to accomplish these goals through the pursuit of four specific aims designed to build capacity for biomedical and cancer research and training at UMass Boston by bridging a gap in the availability of cutting-edge genomics-based tools; support Partnership investigators who wish to pursue early project ideas, especially those that require innovative and/or technically challenging genomics approaches; bridge a training gap between students and high-level genomics-based technologies, and provide bioinformatics analysis of data generated in the core. In this application, the GC specifically supports FP2: Targeting androgen receptor signaling in prostate cancer in men with African Ancestry – Steven Balk (DF/HCC - BIDMC) and Changmeng Cai (UMass Boston) and PP2: High frequency of CHD1 loss in BRCA2-deficient African American prostate tumors drives treatment resistance – Zoltan Szallasi (DF/HCC - BCH) and Shailja Pathania (UMass Boston).

概括 在为健康分散人群服务和代表性不足的机构服务中，通常存在一个危险的差距 学生（ISUPS）在获得基因组技术技术与所需的高成本之间 仪器，技术剖面专业和分析专业知识。 通过为降低的费用提供专家和负担得起的高通量基因组技术的访问 对于所有合作伙伴调查人员 探索早期项目的想法，并与合作伙伴调查人员和培训培训一起促进使用 建立可持续的癌症生物学和癌症差异研究的基因组技术。 这些目标是GC（通过个性化癌症疗法中心的主持，CPCT） 一线基因组学相关技术以及对数据分析的生物信息学支持 通过负担得起的报销模型进行调查。 通过追求四个特定目标，旨在建立生物医学和癌症研究的能力以及 在波士顿的培训中，在基于最先进的基因组学工具方面弥合了差距 希望追求早期项目想法的合作伙伴调查员，尤其是需要创新的研究者 和/或技术上具有挑战性的基因组学方法； 基于基因组学的技术，并为核心中生成的数据提供生物信息学分析 应用GC专门支持FP2：男性前列腺癌中的雄激素受体信号传导 与非洲血统-Steven Balk（DF/HCC -BIDMC）和Changmeng CAI（UMass Boston）和PP2：高 BRCA2缺陷型非裔美国人前列腺肿瘤治疗耐药性的CHD1损失频率 Zoltan Szallasi（DF/HCC -BCH）和Shailja Pathania（波士顿UMass）。